Cargando…

Managing pregnancy in inflammatory rheumatological diseases

Historically, pregnancy in women with many inflammatory rheumatic diseases was not considered safe and was discouraged. Combined care allows these pregnancies to be managed optimally, with the majority of outcomes being favorable. Disease activity at the time of conception and anti-phospholipid anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Varsha, Gordon, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157639/
https://www.ncbi.nlm.nih.gov/pubmed/21371350
http://dx.doi.org/10.1186/ar3227
_version_ 1782210323475857408
author Jain, Varsha
Gordon, Caroline
author_facet Jain, Varsha
Gordon, Caroline
author_sort Jain, Varsha
collection PubMed
description Historically, pregnancy in women with many inflammatory rheumatic diseases was not considered safe and was discouraged. Combined care allows these pregnancies to be managed optimally, with the majority of outcomes being favorable. Disease activity at the time of conception and anti-phospholipid antibodies are responsible for most complications. Disease flares, pre-eclampsia, and thrombosis are the main maternal complications, whereas fetal loss and intrauterine growth restriction are the main fetal complications. Antirheumatic drugs used during pregnancy and lactation to control disease activity are corticosteroids, hydroxychloroquine, sulphasalzine, and azathioprine. Vaginal delivery is possible in most circumstances, with cesarean section being reserved for complications.
format Online
Article
Text
id pubmed-3157639
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31576392011-08-25 Managing pregnancy in inflammatory rheumatological diseases Jain, Varsha Gordon, Caroline Arthritis Res Ther Review Historically, pregnancy in women with many inflammatory rheumatic diseases was not considered safe and was discouraged. Combined care allows these pregnancies to be managed optimally, with the majority of outcomes being favorable. Disease activity at the time of conception and anti-phospholipid antibodies are responsible for most complications. Disease flares, pre-eclampsia, and thrombosis are the main maternal complications, whereas fetal loss and intrauterine growth restriction are the main fetal complications. Antirheumatic drugs used during pregnancy and lactation to control disease activity are corticosteroids, hydroxychloroquine, sulphasalzine, and azathioprine. Vaginal delivery is possible in most circumstances, with cesarean section being reserved for complications. BioMed Central 2011 2011-02-25 /pmc/articles/PMC3157639/ /pubmed/21371350 http://dx.doi.org/10.1186/ar3227 Text en Copyright ©2011 BioMed Central Ltd
spellingShingle Review
Jain, Varsha
Gordon, Caroline
Managing pregnancy in inflammatory rheumatological diseases
title Managing pregnancy in inflammatory rheumatological diseases
title_full Managing pregnancy in inflammatory rheumatological diseases
title_fullStr Managing pregnancy in inflammatory rheumatological diseases
title_full_unstemmed Managing pregnancy in inflammatory rheumatological diseases
title_short Managing pregnancy in inflammatory rheumatological diseases
title_sort managing pregnancy in inflammatory rheumatological diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157639/
https://www.ncbi.nlm.nih.gov/pubmed/21371350
http://dx.doi.org/10.1186/ar3227
work_keys_str_mv AT jainvarsha managingpregnancyininflammatoryrheumatologicaldiseases
AT gordoncaroline managingpregnancyininflammatoryrheumatologicaldiseases